Innovation in Ambulatory Care of Heart Failure in the Era of Coronavirus Disease 2019

Heart Fail Clin. 2020 Oct;16(4):433-440. doi: 10.1016/j.hfc.2020.06.004. Epub 2020 Jun 19.

Abstract

Despite steady progress over the past 3 decades in advancing drug and device therapies to reduce morbidity and mortality in heart failure with reduced ejection fraction, large registries of usual care demonstrate incomplete use of these evidence-based therapies in clinical practice. Potential strategies to improve guideline-directed medical therapy include leveraging non-physician clinicians, solidifying transitions of care, incorporating telehealth solutions, and engaging in comprehensive comorbid disease management via multidisciplinary team structures. These approaches may be particularly relevant in an era of Coronavirus Disease 2019 and associated need for social distancing, further limiting contact with traditional ambulatory clinic settings.

Keywords: Ambulatory; COVID-19; Care optimization; Guideline-directed medical therapy; Heart failure.

Publication types

  • Review

MeSH terms

  • Ambulatory Care* / methods
  • Ambulatory Care* / organization & administration
  • Betacoronavirus
  • Coronavirus Infections* / epidemiology
  • Coronavirus Infections* / prevention & control
  • Heart Failure / epidemiology
  • Heart Failure / therapy*
  • Humans
  • Organizational Innovation
  • Pandemics* / prevention & control
  • Pneumonia, Viral* / epidemiology
  • Pneumonia, Viral* / prevention & control

Supplementary concepts

  • COVID-19
  • severe acute respiratory syndrome coronavirus 2